NZ629867A - Igg stimulated remyelination of peripheral nerves - Google Patents

Igg stimulated remyelination of peripheral nerves

Info

Publication number
NZ629867A
NZ629867A NZ629867A NZ62986713A NZ629867A NZ 629867 A NZ629867 A NZ 629867A NZ 629867 A NZ629867 A NZ 629867A NZ 62986713 A NZ62986713 A NZ 62986713A NZ 629867 A NZ629867 A NZ 629867A
Authority
NZ
New Zealand
Prior art keywords
neuropathy
effective amount
therapeutically effective
medicament
igg
Prior art date
Application number
NZ629867A
Other languages
English (en)
Inventor
Birgit Maria Reipert
Hans-Peter Schwarz
Patrick Kuery
Nevena Tzekova
Hans-Peter Hartung
Corinna Hermann
Hartmut Ehrlich
Sebastian Bunk
Original Assignee
Baxalta Inc
Baxalta GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta Inc, Baxalta GmbH filed Critical Baxalta Inc
Publication of NZ629867A publication Critical patent/NZ629867A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
NZ629867A 2012-02-29 2013-02-28 Igg stimulated remyelination of peripheral nerves NZ629867A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261605117P 2012-02-29 2012-02-29
PCT/US2013/028350 WO2013130826A2 (en) 2012-02-29 2013-02-28 Igg stimulated remyelination of peripheral nerves

Publications (1)

Publication Number Publication Date
NZ629867A true NZ629867A (en) 2016-09-30

Family

ID=47884569

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ629867A NZ629867A (en) 2012-02-29 2013-02-28 Igg stimulated remyelination of peripheral nerves

Country Status (21)

Country Link
US (5) US8986670B2 (enExample)
EP (2) EP2820042B1 (enExample)
JP (3) JP6335800B2 (enExample)
KR (3) KR20200126005A (enExample)
CN (4) CN107551269A (enExample)
AR (2) AR090211A1 (enExample)
AU (3) AU2013203088B2 (enExample)
BR (1) BR112014021240A2 (enExample)
DK (2) DK2820042T3 (enExample)
EA (2) EA032000B1 (enExample)
ES (2) ES2755056T3 (enExample)
FI (1) FI3590960T3 (enExample)
HK (1) HK1248534A1 (enExample)
IL (3) IL277103B2 (enExample)
MX (2) MX369444B (enExample)
NZ (1) NZ629867A (enExample)
PL (2) PL3590960T3 (enExample)
PT (2) PT3590960T (enExample)
SG (1) SG11201405302WA (enExample)
TW (3) TW201838654A (enExample)
WO (1) WO2013130826A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2820042T3 (da) * 2012-02-29 2019-10-28 Baxalta GmbH Igg-stimuleret remyelinisering af perifere nerver
US9690975B2 (en) * 2015-05-28 2017-06-27 Axogen Corporation Quantitative structural assay of a nerve graft
US11511136B2 (en) 2017-11-17 2022-11-29 The Research Foundation For The State University Of New York Method for treating damaged peripheral nerves using x-ray microbeam irradiation
US20220111012A1 (en) * 2019-01-07 2022-04-14 Mallinckrodt Ard Ip Unlimited Company Methods of promoting remyelination
GB201907882D0 (en) 2019-06-03 2019-07-17 Cyprus Foundation For Muscular Dystrophy Res Methods
EP4737584A1 (en) * 2023-06-30 2026-05-06 FUJIFILM Corporation Method for evaluating intercellular interaction of neuroinflammation

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE348942B (enExample) 1970-06-02 1972-09-18 Statens Bakteriologiska Labor
AT376367B (de) 1983-03-16 1984-11-12 Immuno Ag Verfahren zur herstellung von therapeutisch verabreichbaren, in endbehaeltern abgefuellten plasmaderivaten
DK166763C (da) 1983-03-16 1993-07-12 Immuno Ag Immunoglobulin-g-holdig fraktion
DE3473407D1 (en) 1983-05-02 1988-09-22 Immuno Ag Method of inactivating pathogens
AT389815B (de) 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
AT390560B (de) 1986-05-30 1990-05-25 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern
JP2871709B2 (ja) 1988-11-21 1999-03-17 住友製薬株式会社 免疫グロブリンｇ結合活性を有する新規な蛋白質プロテインｈ、該蛋白質をコードする遺伝子及び該蛋白質の製造法
US5177194A (en) 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
WO1992003536A1 (en) * 1990-08-15 1992-03-05 University Of Miami And Its School Of Medicine Autotransplantation of schwann cells to promote nervous system repair
AT402891B (de) 1991-06-20 1997-09-25 Immuno Ag Verfahren zur herstellung eines inaktivierten blutproduktes
JP3133338B2 (ja) 1992-12-16 2001-02-05 イムノ・アクチエンゲゼルシャフト ウイルス的に安全な生物学的組成物の調製方法
FR2706466B1 (fr) 1993-06-14 1995-08-25 Aetsrn Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré.
HRP940645A2 (en) 1993-10-06 1996-12-31 Immuno Ag Process for virus deactivation in the presence of polyalkylene glycol and the pharmaceutical preparation thus obtained
TW491855B (en) 1996-08-07 2002-06-21 Csl Ltd Purification of immunoglobulins
US5886154A (en) 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
IL140155A (en) 1998-06-09 2005-12-18 Statens Seruminstitut Process for producing immunoglobulins for intravenous administration and other immunoglobulin products
SE0001128D0 (sv) 2000-03-30 2000-03-30 Amersham Pharm Biotech Ab A method of producing IgG
EP2287191B1 (en) * 2000-05-10 2016-10-12 Mayo Foundation For Medical Education And Research Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system
FR2824568B1 (fr) 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
JP2003070465A (ja) * 2001-08-31 2003-03-11 Keio Gijuku シュワン細胞の培養方法
UY28170A1 (es) 2003-01-24 2004-07-30 Elan Pharm Inc Preparacion y tratamiento para las enfermedades desmielinizantes y paralisis mediante la aplicacion de agentes remielinizantes.
MXPA06008435A (es) * 2004-01-30 2007-05-23 Suomen Punainen Risti Veripalvelu Proceso de manufactura de una inmunoglobulina libre de virus.
ES2407380T5 (es) 2004-02-27 2017-07-07 Octapharma Ag Procedimiento para proporcionar una preparación de anticuerpos purificada, sin riesgo respecto a virus
NZ578816A (en) * 2007-02-02 2012-06-29 Biogen Idec Inc Use of semaphorin 6a for promoting myelination and oligodendrocyte differentiation
US7854703B2 (en) 2007-09-25 2010-12-21 Intel Corporation Peripheral neuropathy detection
CA2643496C (en) 2008-11-06 2015-02-03 Michael Fehlings The therapeutic use of igg as a neuroprotective agent
CN102021140B (zh) * 2009-09-18 2013-04-24 上海市第一人民医院 一种分离、纯化许旺细胞的方法
DK2820042T3 (da) * 2012-02-29 2019-10-28 Baxalta GmbH Igg-stimuleret remyelinisering af perifere nerver

Also Published As

Publication number Publication date
MX2019012496A (es) 2020-01-20
AU2016201137A1 (en) 2016-03-10
US10494418B2 (en) 2019-12-03
TW201400502A (zh) 2014-01-01
HK1206035A1 (en) 2015-12-31
PL2820042T3 (pl) 2020-03-31
EP2820042A2 (en) 2015-01-07
EA201892521A1 (ru) 2019-07-31
AU2016201137B2 (en) 2017-10-12
IL234303B (en) 2020-09-30
IL277103A (en) 2020-10-29
DK3590960T3 (da) 2023-04-24
WO2013130826A2 (en) 2013-09-06
TWI700297B (zh) 2020-08-01
JP2020059705A (ja) 2020-04-16
CN109966488A (zh) 2019-07-05
CN104302666A (zh) 2015-01-21
SG11201405302WA (en) 2014-09-26
PL3590960T3 (pl) 2023-07-17
IL277103B1 (en) 2025-03-01
CN110343171A (zh) 2019-10-18
US20180291087A1 (en) 2018-10-11
ES2943585T3 (es) 2023-06-14
PT3590960T (pt) 2023-04-18
AU2018200026A1 (en) 2018-01-25
AR117207A2 (es) 2021-07-21
PT2820042T (pt) 2019-10-31
MX369444B (es) 2019-11-08
AU2013203088B2 (en) 2015-12-03
TWI632158B (zh) 2018-08-11
JP2015508824A (ja) 2015-03-23
EP3590960A1 (en) 2020-01-08
EA032000B1 (ru) 2019-03-29
KR20200126005A (ko) 2020-11-05
FI3590960T3 (fi) 2023-04-25
DK2820042T3 (da) 2019-10-28
WO2013130826A3 (en) 2013-12-05
US8986670B2 (en) 2015-03-24
EA201400966A1 (ru) 2014-12-30
AR090211A1 (es) 2014-10-29
AU2018200026B2 (en) 2019-12-05
CN107551269A (zh) 2018-01-09
KR102673154B1 (ko) 2024-06-05
TW201736398A (zh) 2017-10-16
AU2013203088A1 (en) 2013-09-19
IL274512A (en) 2020-06-30
US9834593B2 (en) 2017-12-05
ES2755056T3 (es) 2020-04-21
IL277103B2 (en) 2025-07-01
EP2820042B1 (en) 2019-07-24
KR102170615B1 (ko) 2020-10-28
HK1248534A1 (zh) 2018-10-19
US20200216518A1 (en) 2020-07-09
KR20140134690A (ko) 2014-11-24
US20150232536A1 (en) 2015-08-20
US20130224150A1 (en) 2013-08-29
IL274512B2 (en) 2024-07-01
KR20220045087A (ko) 2022-04-12
TW201838654A (zh) 2018-11-01
EP3590960B1 (en) 2023-03-29
MX2014010387A (es) 2015-09-25
US20210300997A1 (en) 2021-09-30
IL274512B1 (en) 2024-03-01
JP6335800B2 (ja) 2018-05-30
BR112014021240A2 (pt) 2018-09-18
JP6979990B2 (ja) 2021-12-15
JP2018030856A (ja) 2018-03-01
JP6637934B2 (ja) 2020-01-29

Similar Documents

Publication Publication Date Title
SI2625199T1 (en) Procedures for treating psoriasis using IL-17 antagonists
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
BR112013002211A2 (pt) 6-(1-metil-1h-pirazol-4-il)-3-(2-metil-2h-indazol-5-il tio)-[1,2,4]triazolo[43-b] piridazina como um inibidor de c-met
MX360189B (es) Terapia de combinacion para el tratamiento de glioblastoma.
MX2016002645A (es) Tratamiento combinado para tratar el glioblastoma.
EA201201465A1 (ru) Лекарственные формы хинонов для лечения офтальмических заболеваний
EA201591403A1 (ru) Спиролактамные модуляторы рецептора nmda и их применение
BR112017003571A2 (pt) terapia combinada
EA201591687A1 (ru) Индукционная терапия ритуксимабом с последующим лечением с использованием глатирамера ацетата
HK1210593A1 (en) Tetracycline compounds for treating neurodegenerative disorders
UA117570C2 (uk) Спосіб лікування діабету або діабету, спричиненого ожирінням, або ускладнень при діабеті
EA033555B1 (ru) Фармацевтические композиции для лечения серповидно-клеточного нарушения
MY189505A (en) Methylene linked quinolinyl modulators of roryt
BR112022002609A2 (pt) Métodos de tratamento de tumores estromais gastrointestinais
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
MX2015007183A (es) Metodos y composiciones para el tratamiento de mucopolisacaridosis tipo iiia administrado de forma intratecal.
WO2012170918A3 (en) Methods of treatment for retinal diseases
WO2013087654A3 (en) Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation
AU2018200026B2 (en) IgG STIMULATED REMYELINATION OF PERIPHERAL NERVES
HK1214752A1 (zh) 由产甲烷菌引起或与之相关的疾病及病状的诊断、选择及治疗方法
MX339793B (es) Metodos para tratar trastornos resistentes al metotrexato con 10-propargil-10-deaza-aminopterina.
MY163936A (en) Compounds for suppressing a peripheral nerve disorder induced by an anti-cancer agent
EP2563350A4 (en) THERAPEUTIC REGIME AND METHOD FOR THE TREATMENT OR IMPROVEMENT OF VIEW DISORDERS ASSOCIATED WITH ENDOGENOUS RETINOID DEFICIENCY
MX2019009846A (es) Iduronato-2-sulfatasa para usarse en el tratamiento del deterioro cognitivo del sindrome de hunter mediante suministro intratecal.
MX2014013380A (es) Usos de cxcl17, un nuevo marcador de quimiocinas de enfermedad pulmonar y gastrointestinal humana.

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: BAXALTA GMBH, CH

Effective date: 20160414

Owner name: BAXALTA INC, US

Effective date: 20160414

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 FEB 2018 BY COMPUTER PACKAGES INC

Effective date: 20170302

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 FEB 2019 BY ANAQUA SERVICES

Effective date: 20180122

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 FEB 2020 BY ANAQUA SERVICES

Effective date: 20190122

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 FEB 2021 BY ANAQUA SERVICES

Effective date: 20200121

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 FEB 2022 BY ANAQUA SERVICES

Effective date: 20210120

ASS Change of ownership

Owner name: TAKEDA PHARMACEUTICAL COMPANY, JP

Effective date: 20211022

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 FEB 2023 BY ANAQUA SERVICES

Effective date: 20220119

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 FEB 2024 BY ANAQUA SERVICES

Effective date: 20230120

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 FEB 2025 BY ANAQUA SERVICES

Effective date: 20240124

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 FEB 2026 BY ANAQUA SERVICES

Effective date: 20250122